An MRI-targeted prostate biopsy is a biopsy in which tissue cores are deliberately directed into a suspicious prostate lesion that was identified on MRI. Instead of sampling the gland only according to a fixed anatomical template, the radiologist’s MRI location is transferred to the biopsy procedure so the needle can pass through the abnormal tissue itself. The target can be reached using cognitive guidance, MRI-ultrasound software fusion or direct in-bore MRI guidance. Targeted biopsy improves sampling of MRI-visible clinically significant prostate cancer, but it does not make MRI a diagnosis: pathology from the tissue cores still determines whether cancer is actually present and what Grade Group it has.
MRI-targeted biopsy links two separate tests. First, prostate MRI identifies and maps a suspicious lesion. Second, a biopsy needle is directed toward that mapped location to obtain tissue for microscopy. Current EAU guidance recognizes three principal targeting methods—cognitive targeting, ultrasound/MRI software fusion and direct in-bore MRI guidance—and does not establish one of the three as universally superior in cancer detection.
01How Does MRI-Targeted Prostate Biopsy Work?
MRI first gives the lesion an anatomical address
Before a needle can target a lesion, the abnormality has to be localized accurately.
A structured prostate MRI report may describe:
- right or left side;
- peripheral or transition zone;
- anterior or posterior location;
- base, mid-gland or apex;
- largest lesion dimension;
- relationship to the prostate capsule;
- and a PI-RADS score.
That information becomes the biopsy map.
What MRI features make tissue a target?
A suspicious lesion may show a combination of:
- low T2-weighted signal;
- restricted diffusion;
- low ADC signal;
- early focal enhancement when dynamic contrast is used;
- irregular or infiltrative morphology;
- large size;
- or imaging concern for extension beyond the prostate.
The exact weighting of those findings depends on prostate zone.
The imaging biology is explained in Multiparametric Prostate MRI.
Does every visible lesion become a biopsy target?
No.
MRI detects many abnormalities that are not clinically significant prostate cancer.
The biopsy decision incorporates:
- PI-RADS category;
- PSA;
- PSA density;
- DRE findings;
- age;
- family history;
- genetic risk;
- previous biopsy history;
- and the clinical consequences of obtaining a diagnosis.
How does PI-RADS affect the decision?
Can a PI-RADS 3 lesion be monitored without biopsy?
Yes, in selected patients.
Current EAU guidance allows biopsy to be omitted when MRI is PI-RADS 3 and clinical suspicion is very low, including:
- PSA density below approximately 0.10 ng/mL/cc;
- and no important prostate-cancer family history.
Otherwise, targeted biopsy with surrounding regional sampling can be considered.
Can a negative MRI avoid biopsy?
Sometimes.
When MRI is PI-RADS 1–2 and clinical suspicion is low, current EAU guidance allows PSA monitoring rather than immediate biopsy.
One example of a lower-risk setting is:
- PSA density below approximately 0.20 ng/mL/cc;
- and no important family-history concern.
A negative MRI is less reassuring when PSA density is high or hereditary risk is substantial.
Where does PSA density fit?
PSA density relates the blood PSA concentration to prostate volume:
PSA density = PSA ÷ prostate volume.
It is especially useful when deciding what to do with:
- a negative MRI;
- an equivocal PI-RADS 3 lesion;
- or persistent suspicion after a previous negative biopsy.
Can targeted biopsy be done through either biopsy route?
Yes.
MRI targeting and biopsy route are separate choices.
The target can be sampled using:
- a transperineal needle route;
- or a transrectal needle route.
Current MRI-directed biopsy can be performed through either approach under local anesthesia.
For the route comparison, see Transperineal vs Transrectal Prostate Biopsy.
MRI targeting does not remove clinical judgment from the biopsy decision. The lesion must first be important enough to sample. PI-RADS, PSA density, DRE, family history, previous biopsy results and patient health all help determine whether tissue diagnosis is warranted.
02What Is the Difference Between Cognitive, MRI-Ultrasound Fusion and In-Bore Targeted Biopsy?
All three methods use the same MRI lesion but transfer it differently
The target is created on MRI.
What differs is how that location is brought into the biopsy procedure.
1. Cognitive targeting: the operator performs the registration mentally
With cognitive targeting, the clinician:
- reviews the MRI images and prostate sector map;
- identifies the lesion’s relationship to recognizable landmarks;
- visualizes the prostate with ultrasound;
- mentally transfers the MRI location onto the ultrasound anatomy;
- directs the biopsy needle into the expected target.
No dedicated image-fusion software is required.
What are the advantages of cognitive targeting?
- Lower technology burden.
- Can be used in centers without specialized fusion platforms.
- Fast in experienced hands.
- Works through either transperineal or transrectal access.
What is the main limitation?
Cognitive targeting depends heavily on:
- operator MRI understanding;
- three-dimensional spatial reasoning;
- prostate deformation during ultrasound;
- lesion size;
- and lesion location.
Small, apical or difficult anterior targets can be challenging.
2. Software fusion overlays the MRI target onto live ultrasound
In MRI-ultrasound fusion biopsy, dedicated software:
- imports the prior MRI;
- identifies or imports lesion contours;
- maps the prostate boundaries;
- aligns the MRI prostate with live ultrasound;
- and displays the target relative to the biopsy needle.
The goal is to convert the invisible MRI coordinate into a visible procedure target.
Does software fusion eliminate targeting error?
No.
The prostate can change shape between MRI and biopsy because of:
- ultrasound-probe pressure;
- bladder and rectal filling;
- patient positioning;
- needle pressure;
- and differences between supine MRI and biopsy positioning.
Fusion systems mathematically compensate for some deformation, but registration is not perfect.
3. In-bore biopsy samples the target under direct MRI guidance
With direct in-bore biopsy, the patient remains in or returns to an MRI environment during the procedure.
Needle positioning is checked against the lesion directly on MRI rather than transferring the target onto ultrasound.
Potential advantages include:
- direct visualization of the MRI target;
- confirmation of needle position relative to the lesion;
- and fewer non-target cores in some protocols.
Disadvantages include:
- longer scanner occupancy;
- greater resource requirements;
- specialized equipment;
- and limited availability.
Which technique detects more clinically significant cancer?
Current EAU guidance does not identify a clear universal winner among:
- cognitive targeting;
- software fusion;
- and direct in-bore MRI biopsy.
The FUTURE randomized trial compared all three approaches in men with previous negative biopsy and persistent suspicion.
Clinically significant cancer detection was:
- 34% with software fusion;
- 33% with cognitive targeting;
- 33% with in-bore MRI biopsy.
No significant difference was found, although the study was underpowered for a definitive equivalence conclusion.
What does newer 2026 evidence show about cognitive vs software fusion?
The multicenter randomized IMAGINATION trial enrolled 648 men with PI-RADS 3–5 lesions.
Targeted biopsy found clinically significant cancer in approximately:
- 32% with cognitive fusion;
- 34% with software fusion.
Under the trial’s prespecified noninferiority margin, cognitive targeting was noninferior overall.
The trial also reported an interaction with body mass index, with software fusion performing better in heavier patients in that population.
That BMI finding requires cautious extrapolation because the study population was predominantly Asian and the authors specifically called for confirmation in other populations.
Does expensive software automatically mean a better biopsy?
No.
A high-quality biopsy depends on:
- high-quality MRI;
- accurate lesion interpretation;
- correct MRI-to-procedure registration;
- appropriate core placement;
- operator experience;
- and high-quality pathology.
Technology can assist those steps but cannot guarantee them.
Fusion biopsy does not mean “MRI biopsy.” In most software-fusion procedures, the MRI was performed earlier. During the actual biopsy, live ultrasound is used and software overlays the stored MRI target. In-bore biopsy is different because MRI itself guides or confirms needle placement during the procedure.
03Does MRI-Targeted Biopsy Replace Systematic Biopsy?
Targeted biopsy and systematic biopsy answer overlapping but different questions
MRI-targeted biopsy asks:
“What is inside this specific suspicious MRI lesion?”
Systematic biopsy asks:
“Is clinically important cancer present elsewhere in predefined prostate regions?”
Perilesional biopsy asks:
“Does clinically significant tissue extend just beyond the visible MRI target or lie where targeting error could occur?”
Why did MRI-targeted biopsy become important?
Traditional systematic biopsy distributes cores anatomically without knowing whether the needle intersects the most suspicious tissue.
MRI changed that by identifying lesions most likely to contain clinically significant cancer.
This produces two major advantages:
- more efficient sampling of clinically important disease;
- less detection of incidental low-grade Grade Group 1 cancer in many MRI-directed pathways.
What did the PRECISION trial show?
The landmark PRECISION trial randomized 500 biopsy-naïve men.
In the MRI pathway:
- 28% had MRI that was not suggestive of prostate cancer and avoided biopsy;
- clinically significant cancer was detected in 38% of men assigned to the MRI pathway;
- compared with 26% assigned to standard systematic biopsy.
The MRI pathway also diagnosed fewer clinically insignificant cancers.
Do all studies show targeted biopsy alone is sufficient?
No.
MRI-targeted biopsy can miss some cancers that systematic sampling finds.
The MRI-FIRST prospective study illustrated this clearly.
Among clinically significant cancers detected in that study:
- some were detected by targeted biopsy only;
- some by systematic biopsy only;
- and most by both approaches.
The combined approach therefore maximized detection, although it also required more cores and can detect more low-grade disease.
Why is the field moving toward perilesional sampling?
Many cancers missed by target-only biopsy are found near the MRI lesion rather than randomly on the opposite side of the prostate.
This can happen because:
- MRI underestimates microscopic lesion boundaries;
- the target shifts when the prostate is deformed by ultrasound;
- needle trajectory is slightly inaccurate;
- or the highest-grade tissue sits near rather than inside the most conspicuous MRI center.
How many cores should come from an MRI lesion?
Current EAU guidance states that approximately three to five cores are required for proper sampling of an MRI-detected lesion.
AUA/SUO guidance recommends at least two cores per suspicious MRI target.
These statements are not contradictory.
They reflect different minimum recommendations and evidence frameworks.
The actual number can vary with:
- lesion size;
- lesion location;
- targeting technique;
- needle route;
- and whether perilesional samples are included.
What does EAU recommend for PI-RADS 4 or 5?
Current EAU guidance recommends combining:
- targeted biopsy;
- with perilesional sampling
when MRI is positive at PI-RADS 4 or higher.
What does “perilesional” mean in practical terms?
The concept is to sample the tissue immediately around the MRI target rather than automatically performing a full classical systematic biopsy throughout the entire gland.
Research summarized by EAU shows that:
- systematic cores on the opposite MRI-negative side often add relatively little clinically significant cancer detection;
- cores in the same sextant as the lesion or immediately adjacent can add more;
- regional sampling can therefore compensate for targeting imprecision with fewer total cores than full systematic sampling.
What does current evidence say about targeted + perilesional biopsy?
EAU summarizes a meta-analysis in which targeted plus regional/perilesional sampling detected significantly more Grade Group 2 or higher cancer than targeted biopsy alone.
Compared with the classical combination of targeted plus full systematic biopsy, targeted plus regional sampling achieved broadly similar clinically significant cancer detection while using fewer cores and reducing some low-grade overdiagnosis.
Does systematic biopsy still have an important role?
Yes.
Examples include:
- negative MRI with persistently high clinical suspicion;
- selected biopsy-naïve patients where broader gland assessment remains important;
- specific repeat-biopsy situations;
- treatment-planning questions where cancer outside the MRI target matters;
- and selected focal-therapy evaluations.
What does the 2026 ProBIOPSY consensus add?
The international ProBIOPSY consensus was developed to standardize prostate biopsy in the MRI era.
Its major message is that targeted-based strategies are sufficient for many clinical scenarios, but no single sampling pattern gives all information needed for every treatment decision.
The consensus specifically notes that additional contralateral sampling can still be important for selected indications such as focal-therapy candidate assessment.
Does more cores always mean a better biopsy?
No.
More cores can:
- increase sampling burden;
- increase discomfort;
- increase bleeding and swelling;
- potentially increase urinary-retention risk;
- and detect more low-grade disease that may never have become clinically important.
The goal is therefore adequate, strategically located tissue rather than the highest possible core count.
Targeted biopsy is not “one needle into one spot.” A suspicious MRI lesion is usually sampled with multiple cores because needle placement, lesion heterogeneity and microscopic tumor extent can vary across only a few millimeters.
04How Accurate Is MRI-Targeted Biopsy, and Why Can It Miss Prostate Cancer?
Targeting improves precision but does not create a perfect reference standard
MRI-targeted biopsy is highly valuable because it concentrates tissue sampling where clinically significant cancer is most likely.
But there are several opportunities for error:
- MRI may fail to show a cancer;
- the radiologist may underestimate lesion boundaries;
- registration between MRI and ultrasound may be imperfect;
- the prostate can deform during the procedure;
- the needle can pass beside the intended target;
- the target can contain mixed cancer grades;
- and pathology can only examine tissue that was actually sampled.
What is an MRI-invisible cancer?
Some clinically significant prostate cancers do not create enough contrast against the surrounding gland to produce a clear MRI target.
Current EAU evidence cites pooled MRI sensitivity around 91% for Grade Group 2 or higher cancer.
That is high sensitivity, but it is not 100%.
Which targets are harder to biopsy accurately?
Targeting difficulty can increase with:
- small lesions;
- very apical lesions;
- anterior lesions;
- lateral lesions;
- large prostates;
- substantial prostate deformation;
- and lesions poorly visible on real-time ultrasound.
Does biopsy route affect targeting failure?
Sometimes.
Needle geometry differs between transperineal and transrectal biopsy.
Current EAU evidence notes that anterior, apical and lateral targets can be particularly challenging through some transrectal trajectories.
Transperineal access can provide more direct trajectories to these regions.
However, either route can successfully perform MRI-targeted biopsy when the operator and technique are appropriate.
Does operator experience matter?
Yes.
EAU guidance specifically notes that MRI-targeted biopsy accuracy is substantially influenced by operator experience.
High-quality programs rely on feedback between:
- radiologists;
- urologists;
- pathologists;
- and, when surgery occurs, final prostatectomy pathology.
That feedback helps identify:
- which MRI lesions were true cancers;
- which targets were missed;
- where targeting systems were inaccurate;
- and how MRI-estimated tumor boundaries compare with pathology.
What if MRI-targeted biopsy finds cancer?
The tissue is graded by pathology.
The report may include:
- histological cancer type;
- Gleason patterns;
- ISUP Grade Group;
- percentage pattern 4 in Gleason score 7 disease;
- presence or absence of cribriform or intraductal carcinoma;
- number of positive cores;
- and amount of cancer within the tissue samples.
Those pathology findings then combine with:
- PSA;
- MRI;
- clinical stage;
- and additional staging imaging when indicated
to define the cancer’s risk and treatment context.
What if only Grade Group 1 cancer is found?
A diagnosis of Grade Group 1 disease does not automatically mean immediate treatment.
Many appropriately selected men with localized low-risk prostate cancer can be managed with active surveillance.
The decision depends on:
- amount of cancer;
- PSA density;
- MRI findings;
- number and location of positive cores;
- age and health;
- and other pathological features.
What if the target is negative?
A negative MRI-targeted biopsy means cancer was not identified in the submitted target cores.
It does not automatically prove the MRI lesion is harmless.
The appropriate next step depends on how suspicious the original situation remains.
When is a negative targeted biopsy reassuring?
Reassurance is stronger when:
- the lesion was only mildly suspicious;
- PSA density is low;
- targeting quality was good;
- perilesional or appropriate additional sampling was negative;
- PSA remains stable;
- and no strong hereditary risk is present.
When can repeat evaluation be appropriate?
Further assessment can be considered when:
- PI-RADS 4 or 5 suspicion persists;
- PSA density remains high;
- PSA continues rising;
- the lesion grows or becomes more conspicuous;
- the original biopsy may have inadequately sampled the target;
- or inherited risk remains substantial.
Possible next steps can include:
- MRI re-review;
- pathology review;
- repeat PSA and PSA density;
- repeat MRI;
- or repeat targeted biopsy.
Does BRCA2 or strong family history affect the targeting method?
The physical targeting technique does not change solely because someone carries BRCA2.
But inherited risk changes the threshold for reassurance.
The same equivocal or negative MRI may carry different residual risk in a patient with:
- several affected first-degree relatives;
- young prostate-cancer diagnoses in the family;
- or a pathogenic BRCA2 variant.
For that context, see Family History and Hereditary Prostate Cancer and BRCA1, BRCA2 and Prostate Cancer.
Does MRI-targeted biopsy determine cancer stage?
No.
Biopsy determines pathology and grade from sampled tissue.
MRI contributes information about local anatomy.
Stage is established from the broader combination of:
- clinical examination;
- pathology;
- PSA;
- MRI;
- and additional imaging when clinically appropriate.
A successful target hit is not the same as a complete map of the prostate. Targeted biopsy can characterize the MRI-visible lesion very efficiently, but the amount of additional tissue needed outside that target depends on the diagnostic purpose and the patient’s residual risk.
→MRI-Targeted, Perilesional and Systematic Biopsy Compared
| Sampling method | Where the cores go | What it is designed to answer | Main strength | Main limitation |
|---|---|---|---|---|
| MRI-targeted biopsy | Directly through the MRI-defined lesion. | Does this suspicious MRI target contain clinically significant cancer? | Efficiently samples the highest-suspicion tissue. | Can miss cancer outside the target or when registration is inaccurate. |
| Perilesional biopsy | Immediately around the MRI lesion. | Is clinically significant cancer present at or beyond the apparent target margin? | Compensates for targeting error and MRI underestimation of microscopic extent. | Exact spatial definition and core number are not perfectly standardized. |
| Systematic biopsy | Predetermined anatomical prostate regions. | Is cancer present outside known MRI targets? | Surveys broader gland tissue and can find MRI-invisible cancer. | Uses more cores and detects more low-grade disease. |
| Cognitive targeting | MRI location mentally transferred to ultrasound. | Can the operator accurately reach the MRI lesion without fusion software? | Low technology burden and effective in experienced hands. | Operator dependent. |
| Software fusion | Digital MRI target registered onto real-time ultrasound. | Can computer-assisted registration improve spatial targeting? | Visible target overlay and electronic tracking. | Registration can still be imperfect because the prostate deforms. |
| In-bore MRI biopsy | Target sampled with MRI guidance during the procedure. | Can the target be sampled directly under MRI visualization? | Direct target and needle-position confirmation. | Resource-intensive and less widely available. |
?Common Questions About MRI-Targeted Prostate Biopsy
| Question | Practical answer |
|---|---|
| What is an MRI-targeted prostate biopsy? | A biopsy in which needle cores are deliberately directed into a suspicious lesion previously identified on prostate MRI. |
| Does MRI-targeted biopsy diagnose cancer? | The biopsy tissue does. MRI identifies the target; pathology determines whether malignant cells are present. |
| Is MRI-targeted biopsy the same as fusion biopsy? | No. Software fusion is one way to perform MRI-targeted biopsy. Cognitive and direct in-bore targeting are alternatives. |
| What is cognitive targeting? | The operator mentally transfers the lesion location from MRI to real-time ultrasound anatomy. |
| What is MRI-ultrasound fusion biopsy? | Software registers a prior MRI with live ultrasound so the target can be displayed during needle placement. |
| What is in-bore MRI biopsy? | A biopsy in which needle position is guided or confirmed directly with MRI during the procedure. |
| Which targeting technique is most accurate? | Current EAU evidence does not establish one technique as universally superior. |
| What did the FUTURE trial show? | Clinically significant cancer detection was similar among software fusion, cognitive targeting and in-bore MRI biopsy in men undergoing repeat biopsy. |
| What did the 2026 IMAGINATION trial show? | Cognitive targeting was noninferior overall to software fusion under the trial’s prespecified margin, with targeted clinically significant cancer detection around 32% versus 34%. |
| Can MRI-targeted biopsy be transperineal? | Yes. |
| Can MRI-targeted biopsy be transrectal? | Yes. |
| Is transperineal the same as fusion biopsy? | No. Transperineal describes needle route; fusion describes target-registration technology. |
| Does every MRI lesion need targeted biopsy? | No. PI-RADS category, PSA density and overall cancer risk determine whether biopsy is appropriate. |
| Does PI-RADS 3 always need biopsy? | No. Selected very-low-risk patients can be monitored, particularly when PSA density is low and there is no important family history. |
| Does PI-RADS 4 need targeted biopsy? | Current EAU guidance recommends targeted plus perilesional sampling for PI-RADS 4 or higher lesions. |
| Does PI-RADS 5 still need tissue confirmation? | Usually yes. MRI cannot reliably establish Gleason score or Grade Group. |
| How many cores are taken from one MRI target? | EAU evidence supports approximately three to five cores for proper sampling of an MRI lesion, while AUA guidance recommends at least two cores per suspicious target. |
| Why are several cores taken from one lesion? | A lesion can be heterogeneous, needle placement can vary by millimeters and the highest-grade tissue may not occupy the lesion center. |
| What is perilesional sampling? | Additional biopsy cores are taken immediately around the MRI target. |
| Why sample around the lesion? | MRI may underestimate microscopic tumor boundaries and the biopsy needle can deviate slightly from the planned target. |
| Does targeted biopsy replace systematic biopsy? | Not in every patient. The need for broader systematic sampling depends on clinical risk, previous biopsy history and the purpose of the biopsy. |
| Why can systematic biopsy still find cancer? | Some cancers are MRI-invisible or occur outside the visible target. |
| Does targeted biopsy detect less low-grade cancer? | MRI-directed pathways generally reduce detection of Grade Group 1 disease compared with classical systematic biopsy strategies. |
| What did the PRECISION trial show? | Clinically significant cancer was detected in 38% of men assigned to the MRI pathway versus 26% assigned to standard systematic biopsy, while 28% of the MRI group avoided biopsy because MRI was not suspicious. |
| Can a targeted biopsy miss cancer? | Yes. MRI can miss cancer, registration can be inaccurate, the needle can miss the lesion or cancer can extend beyond the visible target. |
| Can a PI-RADS 5 lesion have a negative targeted biopsy? | Yes. Persistent high-suspicion discordance may justify imaging review, pathology review or repeat targeted evaluation. |
| Can the MRI target be benign? | Yes. BPH, inflammation, fibrosis and other benign processes can mimic cancer on MRI. |
| Does MRI-targeted biopsy tell the stage? | No. It establishes tissue pathology and grade; stage requires broader clinical and imaging information. |
| Does MRI-targeted biopsy tell the Gleason score? | Yes indirectly through pathology: the tissue cores obtained by the targeted biopsy are examined microscopically to assign Gleason patterns and Grade Group if cancer is found. |
| What happens after a positive result? | Grade Group, PSA, MRI extent, amount of cancer and staging information are combined before management is chosen. |
| What happens after a negative result? | Follow-up depends on PI-RADS score, PSA density, targeting quality, family/genetic risk and whether the lesion persists. |
ΣKey Clinical Takeaways
- MRI-targeted prostate biopsy directs tissue sampling into a lesion previously identified on MRI.
- MRI identifies the target; biopsy pathology determines whether cancer is present.
- MRI-targeted biopsy is not synonymous with software-fusion biopsy.
- Cognitive, software-fusion and direct in-bore techniques can all perform MRI-targeted biopsy.
- Current EAU evidence does not establish one targeting technique as universally superior.
- The FUTURE randomized trial found similar clinically significant cancer detection among cognitive, software-fusion and in-bore targeting.
- The 2026 IMAGINATION randomized trial found cognitive targeting noninferior overall to software fusion under its prespecified margin.
- Software fusion can make target registration visible but does not eliminate registration error.
- Prostate deformation between MRI and biopsy can alter target alignment.
- In-bore biopsy directly uses MRI during needle guidance but requires greater resources.
- MRI-targeted biopsy can be performed through either a transperineal or transrectal route.
- Biopsy route and targeting method are separate concepts.
- PI-RADS 1–2 generally do not create a suspicious biopsy target.
- Selected very-low-risk PI-RADS 3 lesions can be monitored rather than biopsied immediately.
- PI-RADS 4–5 lesions generally warrant tissue sampling in the diagnostic setting.
- Current EAU guidance recommends targeted plus perilesional sampling when MRI is PI-RADS 4 or higher.
- PSA density materially changes how an MRI lesion is interpreted.
- A negative MRI does not eliminate significant cancer when PSA density or inherited risk remains high.
- Targeted biopsy is designed to sample the most suspicious MRI-visible tissue.
- Perilesional biopsy samples tissue immediately around the MRI target.
- Systematic biopsy samples predefined prostate regions whether MRI shows a lesion or not.
- MRI-targeted biopsy generally improves detection of clinically significant cancer compared with unguided systematic sampling alone.
- MRI-directed pathways generally reduce detection of low-grade Grade Group 1 cancer.
- PRECISION found clinically significant cancer in 38% of men assigned to an MRI pathway versus 26% assigned to standard systematic biopsy.
- Twenty-eight percent of men in the PRECISION MRI arm avoided biopsy because MRI was not suspicious.
- Targeted biopsy alone can still miss clinically significant cancer.
- Some clinically important cancers are MRI-invisible.
- Some cancers lie partly outside the visible MRI target.
- Perilesional cores help compensate for target-registration error and underestimated tumor boundaries.
- EAU evidence suggests approximately three to five cores are needed for proper sampling of an MRI-detected lesion.
- AUA/SUO recommends at least two needle cores per suspicious MRI target.
- More cores do not automatically make a biopsy better.
- The ideal sampling plan depends on whether the goal is diagnosis, repeat biopsy, active-surveillance reassessment or treatment planning.
- The 2026 ProBIOPSY consensus supports tailored targeted and perilesional strategies for many clinical situations.
- No single biopsy strategy supplies all information required for every treatment decision.
- Additional contralateral sampling can still matter for selected focal-therapy assessments.
- Operator experience substantially affects MRI-targeted biopsy accuracy.
- Small, anterior, apical and lateral targets can be technically challenging.
- Transperineal access can provide favorable trajectories to some anterior or apical targets.
- A negative targeted biopsy does not automatically invalidate a persistent PI-RADS 4 or 5 lesion.
- Persistent discordance can justify MRI review, pathology review, repeat PSA-density assessment or repeat biopsy.
- A positive targeted biopsy provides tissue for Gleason grading and ISUP Grade Group assignment.
- Grade Group is not the same as cancer stage.
- A diagnosis of low-risk localized cancer does not automatically require immediate treatment.
- MRI-targeted biopsy is one step in the broader sequence from PSA and cancer suspicion to pathology, staging and individualized management.
Clinical bottom line: MRI-targeted prostate biopsy uses a suspicious MRI lesion as a coordinate for tissue sampling. The target can be transferred to the biopsy using the operator’s cognitive registration, MRI-ultrasound fusion software or direct in-bore MRI guidance. None of these technologies completely removes targeting error, and current evidence does not establish one as universally superior. The major modern question is therefore not simply whether the lesion is targeted, but how well it is sampled and whether tissue immediately around it or elsewhere in the prostate is also needed. Current EAU guidance favors targeted plus perilesional sampling for PI-RADS 4–5 lesions, while broader systematic sampling remains useful in selected patients and treatment-planning settings. MRI identifies where suspicion is highest; pathology from appropriately placed cores establishes what the tissue actually is.
Medical disclaimer: This article provides general medical education about MRI-targeted prostate biopsy. Whether biopsy is required, how many cores should be taken, whether systematic or perilesional sampling is needed, and whether a transperineal or transrectal route is appropriate depend on MRI findings, PSA density, prior biopsy history, prostate anatomy, family/genetic risk, overall health and local expertise.
For the complete diagnostic pathway leading to tissue sampling, see How Prostate Cancer Is Diagnosed. For the procedure itself, including pathology and biopsy methods, see What Is a Prostate Biopsy?. To understand the imaging target before the needle is placed, review What Is a Prostate Lesion?, What Is a Prostate MRI?, Multiparametric Prostate MRI and PI-RADS Scoring. For the difference between needle-entry routes, see Transperineal vs Transrectal Prostate Biopsy. For the blood-test risk that helps determine whether a target should be biopsied at all, see PSA Testing, PSA Density and What Happens After a High PSA?. For hereditary risk that can alter the residual concern after a negative or equivocal result, see Family History and Hereditary Prostate Cancer and BRCA1, BRCA2 and Prostate Cancer. For the full disease pathway, return to the Prostate Cancer hub. The next guide explains prostate biopsy recovery, including bleeding, blood in semen, urinary symptoms, infection warning signs and when normal post-biopsy changes should have settled.
Evidence Sources
- European Association of Urology — Prostate Cancer Diagnostic Evaluation: MRI-targeted biopsy, cognitive versus fusion versus in-bore targeting, target-core requirements, perilesional sampling, MRI pathways and biopsy recommendations.
- The FUTURE Trial — randomized comparison of cognitive, MRI-ultrasound fusion and direct in-bore MRI-targeted biopsy after previous negative biopsy.
- IMAGINATION Trial — 2026 multicenter randomized noninferiority comparison of cognitive versus software-based fusion MRI-targeted prostate biopsy.
- PRECISION Trial — MRI-directed diagnostic pathway and targeted biopsy compared with standard systematic transrectal ultrasound-guided biopsy.
- MRI-FIRST — prospective multicenter evaluation of targeted and systematic prostate biopsy in biopsy-naïve men.
- ProBIOPSY — 2026 international multidisciplinary consensus on MRI-informed targeted, perilesional and indication-specific prostate biopsy strategies.
- American Urological Association / Society of Urologic Oncology — Early Detection of Prostate Cancer: MRI-ultrasound fusion, suspicious-target core number and biopsy-route guidance.
